Although it is hard to explain why ITPA deficiency protects from development of anemia only in the early weeks of PR+TVR treatment, this might be the direct consequence of the increased plasma Rbv levels that have been reported to occur after 4 weeks of treatment with TVR. The gene discussed is ITPA; the disease is anemia (phenotype).